Welcome to our dedicated page for Apyx Medical Corporation SEC filings (Ticker: APYX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating the real story behind Apyx Medical’s helium-plasma technology can be difficult. Figures for Renuvion console sales, OEM generator royalties, and regulatory milestones are scattered through footnotes, exhibits and risk factors that span more than 200 pages. Add in frequent 8-K updates on FDA interactions and you have a research headache investors know too well. Searching for “Apyx Medical SEC filings explained simply” often yields little more than raw documents—until now.
Stock Titan delivers that clarity. Our AI digests every Apyx Medical quarterly earnings report 10-Q filing, provides an Apyx Medical annual report 10-K simplified summary, and offers Apyx Medical 8-K material events explained in plain English. Need Apyx Medical insider trading Form 4 transactions? We stream Apyx Medical Form 4 insider transactions real-time and flag unusual Apyx Medical executive stock transactions Form 4 within seconds. AI-powered highlights, red-flag alerts, and side-by-side comparisons turn dense text into decision-ready insights.
Use the data the way professionals do: review segment revenue swings after a product recall, monitor cash burn tied to clinical studies, or benchmark pay with the latest Apyx Medical proxy statement executive compensation tables. Each filing is linked to practical use cases—sales trends, FDA risk disclosure, guidance—so your Apyx Medical earnings report filing analysis starts with context, not clutter. By understanding Apyx Medical SEC documents with AI, you spend time evaluating opportunities, not flipping pages.
Apyx Medical Corporation reported the outcomes of proposals submitted at its annual meeting. Stockholders elected five directors to serve on the board until the 2026 annual meeting, with each nominee receiving between 18.88 million and 19.11 million votes in favor and 6.77 million broker non-votes recorded in those tallies. Shareholders ratified RSM US LLP as the company’s independent registered public accounting firm by a vote of 25,930,634 in favor. A non-binding advisory vote on executive compensation passed with 18,963,101 votes for. A separate advisory vote on frequency favored a one-year option (9,205,086 votes). Stockholders also approved an amendment to delete the text of Article EIGHTH, with 19,047,016 votes for.
Apyx Medical (NASDAQ:APYX) filed a DEF 14A announcing its 2025 Annual Meeting of Stockholders to be held on August 7, 2025. Shareholders will vote on: five key proposals including the election of five directors, ratification of RSM US LLP as auditors, advisory vote on executive compensation, frequency of future say-on-pay votes, and an amendment to delete Article EIGHTH from the Certificate of Incorporation.
The meeting will take place at 9:00 AM EST at Ruskin Moscou Faltischek's offices in Uniondale, NY. The record date for voting eligibility is June 17, 2025. Proxy materials will be distributed to shareholders starting June 27, 2025.
FAQ
What is the current stock price of Apyx Medical Corporation (APYX)?
What is the market cap of Apyx Medical Corporation (APYX)?
